Baird Financial Group
KNSA icon

Baird Financial Group’s Kiniksa Pharmaceuticals KNSA Stock Holding History

Baird Financial Group’s Portfolio KNSA Stock Details KNSA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.96M Sell
30,708
-9,541
-24% -$495K ﹤0.01% 1109
2026
Q1 		$1.94M Sell
40,249
-1,988
-5% -$88.1K ﹤0.01% 1050
2025
Q4 		$1.74M Sell
42,237
-13,075
-24% -$524K ﹤0.01% 1081
2025
Q3 		$2.15M Hold
55,312
– – ﹤0.01% 1025
2025
Q2 		$1.53M Buy
+55,312
New +$1.41M ﹤0.01% 1086

Other funds holding KNSA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
SSC
Spruce Street Capital New York $510M AUM

Baird Financial Group's KNSA Position: Q2 2026 in Review

Baird Financial Group reduced its Kiniksa Pharmaceuticals (KNSA) stake by 24% in Q2 2026, selling an estimated $495K and leaving 30,708 shares worth $1.96M. The position accounts for ﹤0.01% of the portfolio, ranked #1109.

Baird Financial Group first reported a position in KNSA in Q2 2025 and has held it in 5 quarters since. The position peaked at $2.15M in Q3 2025. 266 funds tracked by Wall St. Rank hold KNSA as of Q2 2026.

  • Baird Financial Group held 30,708 shares of Kiniksa Pharmaceuticals worth $1.96M as of Q2 2026.
  • Baird Financial Group sold 9,541 Kiniksa Pharmaceuticals shares in Q2 2026, an estimated $495K.
  • Kiniksa Pharmaceuticals made up ﹤0.01% of Baird Financial Group's portfolio in Q2 2026, its #1109 holding.
  • Baird Financial Group first reported a position in Kiniksa Pharmaceuticals in Q2 2025 and has held it in 5 quarters since.
  • Baird Financial Group's Kiniksa Pharmaceuticals position peaked at $2.15M in Q3 2025.
  • 266 funds tracked by Wall St. Rank held Kiniksa Pharmaceuticals as of Q2 2026.

Based on Baird Financial Group's 13F filing for Q2 2026, filed 12 Aug 2026.